A report from Oppenheimer reiterates it Outperform rating and lowers it price target from $70 to $57 on DeVry DV.
The report states, “September total enrollment decreased 0.9% y/y. Despite DeVry Undergrad & Carrington concerns, positive growth in enrollment occurred at all currently reporting segments, with DeVry Graduate total enrollment +2% y/y, DeVry Medical (Ross/AUC aggregate) new/total enrollments +23%+6% y/y, and DeVry Brasil new/total enrollments +29%/+18% y/y. We anticipate Chamberlain growth to remain solid."
DV closed yesterday at $46.08.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in